Baseline sampling [Regulatives / Guidelines]

posted by NK – India, 2019-06-26 07:25 (940 d 12:59 ago) – Posting: # 20360
Views: 2,492

Hello everyone,

I have a question with regards to FDA OGD guidance of Dihydroergotamine Nasal Spray" dated February 2019.

The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

As per my understanding, Dihydroergotamine is neither endogenous nor available in the diet, then why baseline value is required?

If it is required, what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

Thanks in advance.

Regards
NK


Edit: URL corrected. [Helmut]

Complete thread:

Activity
 Admin contact
21,833 posts in 4,568 threads, 1,554 registered users;
online 12 (0 registered, 12 guests [including 3 identified bots]).
Forum time: Friday 19:25 CET (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5